A Randomized Phase 2 Trial of 177Lu Radiolabeled Anti-PSMA Monoclonal Antibody J591 in Patients With High-Risk Castrate, Biochemically Relapsed Prostate Cancer

Abstract

Clinical trial has received WCMC IRB and CTSC approval with enrollment of initial 6 subjects at WCMC. An additional 38 subjects enrolled (29 treated) at participating sub-sites. Reports submitted to WCMC DSMB in November 2016 with approval to proceed without modifications.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Sep 01, 2017
Accession Number
AD1050870

Entities

People

  • Scott T Tagawa

Organizations

  • Weill Cornell Medicine

Tags

DTIC Thesaurus Topics

  • Cardiovascular Physiological Phenomena
  • Chemical Synthesis
  • Chemistry
  • Health Services
  • Hematologic Diseases
  • Medical Personnel
  • Oncology
  • Prostate Cancer

Readers

  • Clinical Trial Research.